Podcast: Teva Seeks Label Change for Azilect

This fall, The FDA recommended that Teva Neuroscience’s drug rasagiline, brand name Azilect, should not be granted status “to slow the clinical progression of PD.”Mentioned in this episode:August is Make-A-Will Month, which serves as a reminder of the importance of creating and updating your will. Use this moment to take control of your future and ensure your wishes are respected. Visit michaeljfox.org/plan to learn more and get started.